Establishment Labs Holdings Inc. (ESTA)
| Previous close | 44.66 |
| Open | 44.40 |
| Bid | 43.22 x 200 |
| Ask | 55.46 x 200 |
| Day's range | 43.00 - 44.70 |
| 52-week range | 16.96 - 60.12 |
| Volume | |
| Avg. volume | 360,904 |
| Market cap | 1.216B |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.14 |
| Earnings date | 05 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 64.80 |
Business WireFirst U.S. Women Successfully Receive Breast Augmentation with New FDA Approved Motiva Implants
NEW YORK, October 02, 2024--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that the first patients in the United States have successfully undergone breast augmentation with Motiva® Implants.
Simply Wall St.Top US Growth Companies With High Insider Ownership In September 2024
As the Dow Jones Industrial Average reaches new highs and the S&P 500 and Nasdaq Composite experience slight declines, investors are closely monitoring market movements influenced by inflation data and Federal Reserve policies. In this fluctuating environment, growth companies with high insider ownership can offer a unique advantage, as significant insider stakes often signal confidence in a company's long-term potential.
Business WireEstablishment Labs Receives U.S. FDA Approval for Motiva Implants
NEW YORK, September 26, 2024--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants in primary and revision breast augmentation.
